BERKELEY, Calif., May 8 /PRNewswire-FirstCall/ -- Nile Therapeutics,
Inc. (OTC Bulletin Board: NILT.OB), a biopharmaceutical company focused on
developing therapies for cardiovascular disease, is pleased to announce the
appointment of Jane Moffitt, J.D., LL.M. as its Vice President of
Regulatory Affairs.
"We believe Jane's specific leadership contribution to the launch and
development of natriuretic peptide BNP, Natrecor(R), plus her extensive
regulatory affairs background will be of great value to Nile as we develop
our own natriuretic peptide, CD-NP and cardiovascular pipeline," said Peter
Strumph, Chief Executive Officer of Nile.
Ms. Moffitt has over 30 years of professional experience in regulatory
affairs and corporate and food & drug law for pharmaceutical, device and
biotechnology companies. This experience includes developing clinical
regulatory strategies and leading teams responsible for preparing and
maintaining INDs, NDAs, BLAs and global product launches. Her drug product
expertise includes natriuretic peptides, small molecules and biologics.
Prior to joining Nile, Ms. Moffitt was the West Coast Director of
Operations for SciLucent, a specialty healthcare-focused consulting firm.
Prior to that, Jane was a Senior Vice President of Quality and Regulatory
Affairs at a number of pharmaceutical and medical device companies,
including Revance Therapeutics Inc., Scios, Inc., Collagen Corporation, and
Amsco International Inc., and worked as a corporate attorney at Miles
Laboratories, Inc. At Scios, Ms. Moffitt was a member of the Corporate
Management Committee, started the Government Affairs function and was the
head of the regulatory affairs function. Ms. Moffitt also served as
President, Treasurer and a member of the Board of Directors of Scios R&D,
Inc. and BRP, Inc.
Ms Moffitt holds a B.S. in Biology and Political Science from Dickinson
College, a J.D. from Dickinson School of Law and a LL.M. in Trade
Regulation from New York University School of Law.
About Nile Therapeutics
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company
that develops innovative products for the treatment of cardiovascular
disease and other areas of unmet medical need. Nile is initially focusing
its efforts on developing its lead compound, CD-NP, a novel chimeric
natriuretic peptide in clinical studies for the treatment of heart failure,
and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent
with nitric oxide donating properties. A key component of the company's
strategy is to acquire the global rights to additional compounds to expand
its portfolio. More information on Nile can be found at http://www.nilethera.com.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that
involve substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release regarding
our strategy, future operations, outlook, milestones, the success of Nile's
product development, future financial position, future financial results,
plans and objectives of management are forward-looking statements. We may
not actually achieve these plans, intentions or expectations and Nile
cautions investors not to place undue reliance on our forward-looking
statements. Actual results or events could differ materially from the
plans, intentions and expectations disclosed in the forward-looking
statements we make. Various important factors that could cause actual
results or events to differ materially from the forward-looking statements
that we make are described in greater detail in the reports we file with
Securities and Exchange Commission, including the "Risk Factors" section in
Item 1 of the Form 10-KSB we filed with the Securities and Exchange
Commission on March 27, 2008. Nile is providing this information as of the
date of this press release and does not undertake any obligation to update
any forward-looking statements as a result of new information, future
events or otherwise.
SOURCE Nile Therapeutics, Inc.
 back to top
Related links:
http://www.nilethera.com
CONTACT:
Daron Evans, Chief Financial Officer, Nile
Therapeutics, Inc., +1-415-875-7882, info@nilethera.com
|
